Palm Ulrich, Keeser Daniel, Hasan Alkomiet, Kupka Michael J, Blautzik Janusch, Sarubin Nina, Kaymakanova Filipa, Unger Ina, Falkai Peter, Meindl Thomas, Ertl-Wagner Birgit, Padberg Frank
Department of Psychiatry and Psychotherapy, Ludwig Maximilian University Munich, Munich, Germany;
Institute for Clinical Radiology, Ludwig Maximilian University Munich, Munich, Germany;
Schizophr Bull. 2016 Sep;42(5):1253-61. doi: 10.1093/schbul/sbw041. Epub 2016 Apr 20.
Negative symptoms are highly relevant in the long-term course of schizophrenia and are an important target domain for the development of novel interventions. Recently, transcranial direct current stimulation (tDCS) of the prefrontal cortex has been investigated as a treatment option in schizophrenia. In this proof-of-concept study, 20 schizophrenia patients with predominantly negative symptoms were randomized to either 10 sessions of add-on active (2 mA, 20min) or sham tDCS (anode: left DLPFC/F3; cathode: right supraorbital/F4). Primary outcome measure was the change in the Scale for the Assessment of Negative Symptoms (SANS) sum score; secondary outcomes included reduction in Positive and Negative Syndrome Scale (PANSS) scores and improvement of depressive symptoms, cognitive processing speed, and executive functioning. Sixteen patients underwent 4 functional connectivity magnetic resonance imaging (fcMRI) scans (pre and post 1st and pre and post 10th tDCS) to investigate changes in resting state network connectivity after tDCS. Per-protocol analysis showed a significantly greater decrease in SANS score after active (-36.1%) than after sham tDCS (-0.7%). PANSS sum scores decreased significantly more with active (-23.4%) than with sham stimulation (-2.2%). Explorative analysis of fcMRI data indicated changes in subgenual cortex and dorsolateral prefrontal cortex (DLPFC) connectivity within frontal-thalamic-temporo-parietal networks. The results of this first proof-of-concept study indicate that prefrontal tDCS may be a promising intervention for treatment of schizophrenia with predominant negative symptoms. Large-scale randomized controlled studies are needed to further establish prefrontal tDCS as novel treatment for negative symptoms in schizophrenia.
Prog Neuropsychopharmacol Biol Psychiatry. 2020-1-10
Eur Arch Psychiatry Clin Neurosci. 2017-12-6
Schizophrenia (Heidelb). 2025-7-29
Adv Neurobiol. 2024
Schizophr Res Cogn. 2024-10-23
Neurosci Biobehav Rev. 2016-2
Eur Arch Psychiatry Clin Neurosci. 2015-10